a Department of Emergency Medicine, Division of Medical Toxicology, University of Massachusetts Medical School and Umass Memorial Medical Center , Worcester , MA , USA.
b Division of Emergency Medicine, Washington University School of Medicine , St. Louis , MO , USA.
Clin Toxicol (Phila). 2019 Sep;57(9):753-759. doi: 10.1080/15563650.2019.1583342. Epub 2019 Mar 4.
Despite widespread recognition of the opioid crisis, opioid overdose remains a common reason for Emergency Department (ED) utilization. Treatment for these patients after stabilization often involves the provision of information for outpatient treatment options. Ideally, an ED visit for overdose would present an opportunity to start treatment for opioid use disorder (OUD) immediately. Although widely recognized as effective, opioid agonist therapy with methadone and buprenorphine commonly referred to as "medication-assisted therapy" but more correctly as "medication for addiction treatment" (MAT), can be difficult to access even for motivated individuals due to shortages of prescribers and treatment programs. Moreover, opioid agonist therapy may not be appropriate for all patients, as many patients who present after overdose are not opioid dependent. More treatment options are required to successfully match patients with diverse needs to an optimal treatment plan in order to avoid relapse. Naltrexone, a long-acting opioid antagonist, available orally and as a monthly extended-release intramuscular injection, may represent another treatment option. We conducted a literature search of MEDLINE and PubMed. We aimed to capture references related to naltrexone and is use as MAT for OUD, as well as manuscripts that discussed naltrexone in comparison toother agents used for MAT, opioid detoxification, and naltrexone metabolism. Our initial search logic returned a total of 618 articles. Following individual evaluation for relevance, we selected 65 for in-depthreview. Manuscripts meeting criteria were examined for citations meriting further review, leading to the addition of 30 manuscripts Here, we review the pharmacology of naltrexone as it relates to OUD, its history of use, and highlight recent studies and new approaches for use of the drug as MAT including its potential initiation after ED visit for opioid overdose.
尽管阿片类药物危机已得到广泛认识,但阿片类药物过量仍然是急诊就诊的常见原因。这些患者在稳定后接受的治疗通常包括提供门诊治疗选择的信息。理想情况下,阿片类药物过量的急诊就诊应该提供一个机会,立即开始治疗阿片类药物使用障碍(OUD)。尽管阿片类激动剂治疗(美沙酮和丁丙诺啡)被广泛认为是有效的,通常被称为“药物辅助治疗”,但更准确地称为“治疗成瘾的药物”(MAT),但由于缺乏处方者和治疗计划,即使对于有动机的个体,也很难获得。此外,阿片类激动剂治疗可能并不适合所有患者,因为许多在过量后出现的患者并不依赖阿片类药物。需要更多的治疗选择来成功地将具有不同需求的患者与最佳治疗计划相匹配,以避免复发。纳曲酮,一种长效阿片类拮抗剂,可口服和每月肌肉注射长效释放剂,可能代表另一种治疗选择。我们对 MEDLINE 和 PubMed 进行了文献检索。我们旨在捕获与纳曲酮和将其作为 OUD 的 MAT 相关的参考文献,以及讨论纳曲酮与用于 MAT、阿片类药物解毒和纳曲酮代谢的其他药物相比的手稿。我们最初的搜索逻辑总共返回了 618 篇文章。在单独评估相关性后,我们选择了 65 篇进行深入审查。符合标准的手稿被检查了值得进一步审查的引文,导致增加了 30 篇手稿。在这里,我们回顾了纳曲酮与 OUD 相关的药理学、它的使用历史,并强调了最近关于该药物作为 MAT 的使用的研究和新方法,包括在急诊就诊治疗阿片类药物过量后可能开始使用该药。